DURHAM, NC  –  February 4, 2021 – Bioventus Inc. (« Bioventus » or the “Company”), today announced that it has commenced the initial public offering of its Class A common stock. Bioventus is offering 7,350,000 shares of its Class A common stock. The initial public offering price is expected to be between $16.00 and $18.00 per share. Bioventus expects to grant the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of its common stock at the initial public offering price to cover over-allotments. The shares are expected to trade on the Nasdaq Global Select Market under the ticker symbol “BVS.”

Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are serving as joint lead book-running managers and as representatives of the underwriters for the proposed offering. Canaccord Genuity LLC is acting as lead manager for the offering.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the proposed offering may be obtained from any of the following sources:

  • Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at [email protected];
  • P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at [email protected]; or
  • Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected].

A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Investors
Bioventus Investor Relations
[email protected]

Media
Thomas Hill
[email protected]